Rokok

01Pathophysiology

Nicotine exerts its central effects by binding to nicotinic acetylcholine receptors (nAChRs), most importantly the alpha-4/beta-2 (α4β2) subtype located on dopaminergic neurons in the ventral tegmental area (VTA). When nicotine activates these receptors, it triggers a surge of dopamine release into the nucleus accumbens, the brain's core reward center. This dopamine surge is what produces the pleasurable, calming, and concentration-enhancing effects of smoking.

With chronic, repeated nicotine exposure, the brain undergoes a compensatory upregulation of nAChRs. The total number of receptors on the neuronal surface increases substantially because the brain is attempting to maintain homeostasis in the face of constant receptor stimulation. As long as the patient continues to smoke, these extra receptors remain occupied and the system stays in balance.

The moment nicotine is abruptly removed, the problem becomes clear: there are now far more receptors than there is endogenous acetylcholine to stimulate them. This creates a functional state of cholinergic and dopaminergic underactivity in the mesolimbic pathway. The result is the classic withdrawal syndrome: irritability and frustration (loss of reward signaling), anxiety and restlessness (unopposed stress-circuit activation), depressed mood (dopamine deficit), difficulty concentrating (loss of nicotine's pro-cognitive cholinergic effect), increased appetite and weight gain (nicotine normally suppresses appetite via hypothalamic pathways and increases basal metabolic rate), and insomnia (disruption of sleep-wake neurotransmitter balance).

The timeline of withdrawal is predictable and often tested. Symptoms begin within 2 to 12 hours of the last cigarette, peak at 24 to 72 hours, and gradually improve over 2 to 4 weeks. However, cravings can persist for months to years, driven by conditioned environmental cues that reactivate reward-associated memory circuits.

02Classification and Clinical Manifestation

03Diagnostic Workup

Nicotine withdrawal is a clinical diagnosis. When a vignette describes a patient who has recently quit or significantly reduced cigarette use and develops at least four of the cardinal symptoms listed above within 24 hours, the answer is nicotine withdrawal. You do not need to order labs to make this diagnosis.

The Fagerstrom Test for Nicotine Dependence is the most commonly referenced screening instrument in the exam context. Two questions from this tool are particularly high-yield: (1) "How soon after waking do you smoke your first cigarette?" and (2) "How many cigarettes per day do you smoke?" A patient who smokes within 5 minutes of waking and consumes more than 30 cigarettes per day is at the highest tier of dependence and is expected to have the most severe withdrawal.

Cotinine testing and exhaled CO are adjunctive tools used primarily in cessation clinics and research settings. They are not part of the diagnostic criteria but may appear in a question stem to confirm or refute active tobacco use.

04Management and Treatment

Step 1: Behavioral Counseling for Every Patient. The 5 A's framework is the recommended approach and should be offered universally, regardless of whether pharmacotherapy is also used. (1) Ask about tobacco use at every visit. (2) Advise the patient to quit in a clear, personalized manner. (3) Assess willingness to make a quit attempt. (4) Assist by providing a quit plan, pharmacotherapy, and resources. (5) Arrange a follow-up contact within the first week after the quit date.

Step 2: Select Pharmacotherapy Based on Patient Profile. For most patients ready to quit, varenicline is the preferred first-line agent based on evidence of superior efficacy compared to NRT monotherapy or bupropion alone. Varenicline works by partially stimulating the α4β2 receptor (providing a low level of dopamine release to reduce cravings and withdrawal) while simultaneously blocking nicotine from fully activating the receptor if the patient relapses. This dual mechanism is why it is the highest-yield drug to know.

Bupropion SR is an excellent alternative, particularly in patients with comorbid depression, as it has independent antidepressant properties. It is contraindicated in patients with a seizure disorder, current or prior eating disorder (anorexia nervosa or bulimia nervosa), or concurrent use of MAO inhibitors, as bupropion lowers the seizure threshold.

NRT is appropriate for patients who prefer an over-the-counter option or have contraindications to varenicline or bupropion. Combination NRT (patch for baseline control plus gum or lozenge for breakthrough cravings) has been shown to be more effective than a single NRT product and is recommended by current guidelines.

Step 3: Timing Matters. Both varenicline and bupropion must be started before the quit date (1 week for varenicline, 1 to 2 weeks for bupropion) to allow steady-state drug levels to build up before the patient stops smoking. NRT, by contrast, is started on the quit date itself. Patients should not smoke while using NRT, as the additive nicotine can cause toxicity (nausea, tachycardia, hypertension).

Step 4: Manage Relapse. If a patient relapses, the appropriate response is to re-engage them in counseling, reassess pharmacotherapy, and set a new quit date. Relapse is common (most smokers require multiple quit attempts) and should not be treated as failure.

Contraindications and Cautions

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on nicotine withdrawal questions is by overthinking the diagnosis. The vignette will describe a patient who recently quit smoking and now presents with a constellation of mood and behavioral symptoms. Students often jump to a primary psychiatric diagnosis (GAD, MDD, adjustment disorder) because the symptoms overlap. The key to getting the question right is recognizing the temporal relationship: the symptoms began within hours to days of smoking cessation. If the timeline fits, the answer is nicotine withdrawal, not a new psychiatric disorder.

A second major trap involves pharmacotherapy selection. Students frequently confuse the mechanisms and contraindications of varenicline and bupropion. Remember: Varenicline is a partial agonist (stimulates the receptor just enough to ease withdrawal while blocking nicotine's full effect if the patient smokes). Bupropion is a norepinephrine-dopamine reuptake inhibitor with a seizure risk profile. If the vignette includes a history of seizures or an eating disorder, bupropion is the wrong answer.

A third testing point is the timing of drug initiation. Both varenicline and bupropion are started before the quit date, not on the day of cessation. NRT is started on the quit date. This distinction is a favorite "next best step" question format.

Finally, for pregnant patients, the tested answer is almost always behavioral counseling first. Pharmacotherapy in pregnancy is reserved for patients who cannot quit with counseling alone, and when used, short-acting NRT (gum or lozenge) is preferred to minimize sustained fetal nicotine exposure.

The core competency being tested is the ability to recognize a substance withdrawal syndrome based on its temporal pattern, select appropriate pharmacotherapy while respecting contraindications, and apply the correct sequencing of behavioral and pharmacologic interventions.